Journal article
Combination Intravesical Therapy
Urologic clinics of North America, Vol.47(1), pp.83-91
02/01/2020
DOI: 10.1016/j.ucl.2019.09.010
PMID: 31757303
Abstract
After Bacillus Calmette-Guerin (BCG) failure, there is likely a 6- to 24-month window whereby salvage intravesical therapy might allow for preservation of the bladder without disease worsening. Combination intravesical, salvage therapy for nonmuscle invasive bladder cancer represents a promising avenue for treatment in patients unfit or unwilling to undergo cystectomy. BCG with concomitant immune stimulating agents or immune checkpoint inhibitors, combination chemotherapy regimens, such as gemcitabine and docetaxol, and novel agents currently in clinical trials provide hope for a bladder-sparing alternative for patients after BCG failure.
Details
- Title: Subtitle
- Combination Intravesical Therapy
- Creators
- Nathan A. Brooks - University of IowaMichael A. O'Donnell - Univ Iowa Hosp & Clin, Dept Urol, 200 Hawkins Dr, Iowa City, IA 52242 USA
- Resource Type
- Journal article
- Publication Details
- Urologic clinics of North America, Vol.47(1), pp.83-91
- Publisher
- Elsevier
- DOI
- 10.1016/j.ucl.2019.09.010
- PMID
- 31757303
- ISSN
- 0094-0143
- eISSN
- 1558-318X
- Number of pages
- 10
- Grant note
- John and Carol Walter Family Foundation
- Language
- English
- Date published
- 02/01/2020
- Academic Unit
- Urology
- Record Identifier
- 9984320859402771
Metrics
6 Record Views